AU2008348816B2 - 4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidine-2-amine derivatives - Google Patents

4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidine-2-amine derivatives Download PDF

Info

Publication number
AU2008348816B2
AU2008348816B2 AU2008348816A AU2008348816A AU2008348816B2 AU 2008348816 B2 AU2008348816 B2 AU 2008348816B2 AU 2008348816 A AU2008348816 A AU 2008348816A AU 2008348816 A AU2008348816 A AU 2008348816A AU 2008348816 B2 AU2008348816 B2 AU 2008348816B2
Authority
AU
Australia
Prior art keywords
tumour
compound
group
pyrrolo
receptor modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008348816A
Other languages
English (en)
Other versions
AU2008348816A1 (en
Inventor
Dieter Dorsch
Eugen Merkul
Thomas J. J. Mueller
Christian Sirrenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2008348816A1 publication Critical patent/AU2008348816A1/en
Application granted granted Critical
Publication of AU2008348816B2 publication Critical patent/AU2008348816B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2008348816A 2008-01-22 2008-12-23 4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidine-2-amine derivatives Ceased AU2008348816B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008005493.3 2008-01-22
DE102008005493A DE102008005493A1 (de) 2008-01-22 2008-01-22 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
PCT/EP2008/011098 WO2009092431A1 (de) 2008-01-22 2008-12-23 4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidin-2-amin-derivative

Publications (2)

Publication Number Publication Date
AU2008348816A1 AU2008348816A1 (en) 2009-07-30
AU2008348816B2 true AU2008348816B2 (en) 2011-10-20

Family

ID=40386204

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008348816A Ceased AU2008348816B2 (en) 2008-01-22 2008-12-23 4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidine-2-amine derivatives

Country Status (14)

Country Link
US (1) US20100292262A1 (enExample)
EP (1) EP2231664A1 (enExample)
JP (1) JP5524864B2 (enExample)
KR (1) KR20100112626A (enExample)
CN (1) CN101918404A (enExample)
AR (1) AR070212A1 (enExample)
AU (1) AU2008348816B2 (enExample)
BR (1) BRPI0821936A2 (enExample)
CA (1) CA2712612A1 (enExample)
DE (1) DE102008005493A1 (enExample)
IL (1) IL206905A0 (enExample)
MX (1) MX2010007927A (enExample)
WO (1) WO2009092431A1 (enExample)
ZA (1) ZA201005959B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
JP2014515368A (ja) 2011-05-26 2014-06-30 第一三共株式会社 プロテインキナーゼ阻害剤としての複素環化合物
PH12015501130B1 (en) 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
MX370588B (es) * 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
WO2016062792A1 (en) * 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New compounds as nik inhibitors
JP6616411B2 (ja) 2014-10-23 2019-12-04 ヤンセン ファーマシューティカ エヌ．ベー． 新規な、ｎｉｋ阻害剤としてのピラゾール誘導体
AU2015334914B2 (en) 2014-10-23 2019-09-19 Janssen Pharmaceutica Nv New thienopyrimidine derivatives as NIK inhibitors
EA033237B1 (ru) 2014-10-23 2019-09-30 Янссен Фармацевтика Нв Новые производные пиразолопиримидина в качестве ингибиторов nik, фармацевтическая композиция и лекарственное средство, содержащее ее
JP2021535198A (ja) 2018-08-17 2021-12-16 ピーティーシー セラピューティクス， インコーポレイテッド 膵臓癌を治療する方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2007107221A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005123672A2 (en) * 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
CN101801971A (zh) * 2005-09-30 2010-08-11 沃泰克斯药物股份有限公司 可用作janus激酶抑制剂的脱氮嘌呤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2007107221A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate

Also Published As

Publication number Publication date
CN101918404A (zh) 2010-12-15
ZA201005959B (en) 2011-04-28
JP2011510028A (ja) 2011-03-31
WO2009092431A1 (de) 2009-07-30
IL206905A0 (en) 2010-12-30
JP5524864B2 (ja) 2014-06-18
MX2010007927A (es) 2010-08-09
CA2712612A1 (en) 2009-07-30
AR070212A1 (es) 2010-03-25
DE102008005493A8 (de) 2010-03-25
US20100292262A1 (en) 2010-11-18
BRPI0821936A2 (pt) 2015-06-16
KR20100112626A (ko) 2010-10-19
DE102008005493A1 (de) 2009-07-23
AU2008348816A1 (en) 2009-07-30
EP2231664A1 (de) 2010-09-29

Similar Documents

Publication Publication Date Title
AU2008266584B2 (en) 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine derivatives
AU2012213775B2 (en) 7-Azaindole derivatives
AU2010244772B2 (en) 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridine derivates
US8420820B2 (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
AU2008348816A1 (en) 4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidine-2-amine derivatives
AU2011325479B2 (en) 7-([1,2,3]triazol-4-yl)-pyrrolo[2,3-b]pyrazine derivatives
AU2007229070A1 (en) 4-(pyrrolopyridinyl)pyrimidinyl-2-amine derivatives
AU2011335450A1 (en) 3-Hetaryl-substituted pyrrolo[2,3-b]pyridine derivatives as PDK1 inhibitors
AU2010335639B2 (en) Pyrrolo[2,3-d]pyrazin-7-yl pyrimidine compounds
AU2008217297B2 (en) 4-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives
AU2006326768A1 (en) Hydroxyquinoline derivatives
HK1140203A (en) 4-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives
AU2011355362A1 (en) 5-([1,2,3]triazole-4-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives
HK1142332A (en) 6-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aids

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired